Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 13/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6030270 | 0.97 | EPHX1 (0.50) | EPHX1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL6030460 | 0.84 | EPHX1 (0.54) | EPHX1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL6030533 | 0.83 | HSD17B10 (0.44) | EPHX1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL6030766 | 0.81 | HSD17B10 (0.44) | EPHX1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL6031092 | 0.79 | RXFP1 (0.59) | ALDH1A1MEN1KMT2AHSD17B10ALOX15 | |
| SCHEMBL6031509 | 0.76 | HSD17B10 (0.54) | ALDH1A1MEN1KMT2AHSD17B10RXFP1 | |
| SCHEMBL6030418 | 0.76 | HSD17B10 (0.54) | EPHX1ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL6031306 | 0.76 | HSD17B10 (0.54) | EPHX1ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL6031439 | 0.76 | HSD17B10 (0.54) | EPHX1ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL6031060 | 0.76 | HSD17B10 (0.54) | EPHX1ALDH1A1MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064122-B2 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1467978-A4 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1467978-A1 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003053944-A1 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | PNLIP, LIPC, CEL | EPHX1 938/4885ALDH1A1 1832/4885HTT 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.